The online version of this article (https://doi.org/10.1007/s00125-018-4601-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
The aim of the study was to examine the association between lipoprotein-associated phospholipase A2 (Lp-PLA2) activity levels and incident diabetic retinopathy and change in retinopathy grade.
This was a cohort study of diabetic participants with serum collected at baseline and routinely collected diabetic retinal screening data. Participants with type 2 diabetes from the GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland) cohort were used. This cohort is composed of individuals of white Scottish ancestry from the Tayside region of Scotland. Survival analysis accounting for informative censoring by modelling death as a competing risk was performed for the development of incident diabetic retinopathy from a disease-free state in a 3 year follow-up period (n = 1364) by stratified Lp-PLA2 activity levels (in quartiles). The same analysis was performed for transitions to more severe grades.
The hazard of developing incident diabetic retinopathy was 2.08 times higher (95% CI 1.64, 2.63) for the highest quartile of Lp-PLA2 activity compared with the lowest. Higher Lp-PLA2 activity levels were associated with a significantly increased risk for transitions to all grades. The hazards of developing observable (or more severe) and referable (or more severe) retinopathy were 2.82 (95% CI 1.71, 4.65) and 1.87 (95% CI 1.26, 2.77) times higher for the highest quartile of Lp-PLA2 activity compared with the lowest, respectively.
Higher Lp-PLA2 levels are associated with increased risk of death and the development of incident diabetic retinopathy, as well as transitions to more severe grades of diabetic retinopathy. These associations are independent of calculated LDL-cholesterol and other traditional risk factors. Further, this biomarker study shows that the association is temporally sensitive to the proximity of the event to measurement of Lp-PLA2.
ESM (PDF 701 kb)125_2018_4601_MOESM1_ESM.pdf
Williams R, Airey M, Baxter H et al (2004) Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond) 18:963–983 CrossRef
Varma R (2016) Diabetic retinopathy: challenges and future directions. Am J Ophthalmol 141:539–541 CrossRef
Heart Protection Study Collaborative Group (2010) Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 268:348–358 CrossRef
Acharya NK, Levin EC, Clifford PM et al (2013) Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis 35:179–198 PubMed
Hébert HL, Shepherd B, Milburn K et al (2017) Cohort profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). Int J Epidemiol https://doi.org/10.1093/ije/dyx140
Koenig W, Twardella D, Brenner H, Rothenbacher D (2006) Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26:1586–1593 CrossRefPubMed
Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B 34:187–220
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509 CrossRef
- Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study
Moneeza K. Siddiqui
Alexander S. F. Doney
Ewan R. Pearson
Andrew D. Morris
Megan M. McLaughlin
Rachel E. Williams
Colin N. A. Palmer
- Springer Berlin Heidelberg
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II